HALISTER: Bristol Raises EPS View After 3Q Beats, Approves New $3b Buyback

Bristol Raises EPS View After 3Q Beats, Approves New $3b Buyback

(Bloomberg) -- Bristol-Myers now sees 2016 adj. EPS $2.80-$2.90, saw $2.55-$2.65 on July 28, est. $2.62 (range $2.49-$2.71).
  • Sees 2017 adj. EPS $2.85-$3.05, est. $2.91
  • Sees 2016 global revenue increasing in high-teens
  • Says new $3b buyback is incremental to current repurchase program that has ~$1.1b remaining
  • NOTE: BMY market cap $82.4b: Bloomberg data
  • 3Q adj. EPS 77c, est. 65c
  • 3Q revenue $4.92b, est. $4.79b
    • Opdivo $920m, est. $934.2m
    • Eliquis $884m, est. $835.6m
    • Orencia $572m, est. $597.3m
    • Sprycel $472m, est. $445.9m
    • Hepatitis C franchise $379m, est. $363.4m
    • Baraclude $306m, est. $285m
    • Sustiva $275m, est. $269.4m
    • Yervoy $285m, est. $249.5m
  • Conf. call 10:30am 877-258-2708, pw 91351854 or listen to it on LIVE
  • NOTE: Analysts focused on Opdivo outlook, potential buyback; see earnings preview
Link to statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
BMY US (Bristol-Myers Squibb Co)
4528 JP (Ono Pharmaceutical Co Ltd)
4578 JP (Otsuka Holdings Co Ltd)

To de-activate this alert, click here

UUID: 7947283